Phio Pharmaceuticals (PHIO) Liabilities and Shareholders Equity (2011 - 2026)

Phio Pharmaceuticals (PHIO) has 16 years of Liabilities and Shareholders Equity data on file, last reported at $17.4 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 29.55% year-over-year to $17.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $61.7 million (up 103.39% YoY) and the FY2025 annual result came in at $21.5 million, up 274.47% from the prior year.
• Liabilities and Shareholders Equity retreated to $17.4 million in Q1 2026, from $21.5 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $22.2 million in Q1 2022 to a low of $5.3 million in Q2 2024.
• A 5-year average of $12.3 million and a median of $11.5 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity slumped 56.93% — and 2025, when it jumped 274.47%.
• Tracing PHIO's Liabilities and Shareholders Equity over 5 years: stood at $12.8 million in 2022, then dropped by 26.92% to $9.4 million in 2023, then sank by 38.72% to $5.7 million in 2024, then jumped by 274.47% to $21.5 million in 2025, then slipped by 18.96% to $17.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $17.4 million (Q1 2026), $21.5 million (Q4 2025), and $11.5 million (Q3 2025), per Business Quant data.